JAK Inhibitor Compound and Pharmaceutical Composition Patent

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Patent US12590088B2 to Korea Pharma Co., Ltd. on March 31, 2026, covering a JAK inhibitor compound and pharmaceutical composition. The patent claims 4 items related to compounds of Formula I and their use in treating inflammatory, autoimmune, myeloproliferative diseases, and human cancers by regulating JAK kinase signal transduction.

View original document View source feed page

What changed

USPTO issued Patent US12590088B2 to Korea Pharma Co., Ltd. on March 31, 2026, granting exclusive rights to a JAK (Janus Kinase) inhibitor compound of Formula I and pharmaceutical compositions containing it. The patent, filed on May 27, 2020 (Application No. 17613291), covers compounds that regulate signal transduction at the JAK kinase level for therapeutic effects against inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers. Four claims were allowed under CPC classifications including C07D 471/04.

This is a routine patent grant notice with no immediate compliance obligations for other entities. Pharmaceutical companies developing JAK inhibitors should review this patent to assess potential freedom-to-operate concerns or licensing opportunities. Competitors in the inflammatory/autoimmune therapeutic space should conduct IP due diligence to ensure their compounds do not infringe the allowed claims.

Source document (simplified)

← USPTO Patent Grants

Jak inhibitor compound and pharmaceutical composition including the same

Grant US12590088B2 Kind: B2 Mar 31, 2026

Assignee

KOREA PHARMA CO., LTD.

Inventors

Soosung Kang, Eun Sun Park, Eun Hee Park, Seung Hee Han

Abstract

The present invention relates to a JAK inhibitor compound and a pharmaceutical composition including the same. More specifically, the present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutical composition including the same. The structure of the compound of Formula I is described in the specification. The compound of the present invention can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases.